What is Pathalys Pharma?
Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company dedicated to developing innovative therapeutics for unmet medical needs, particularly in the management of End-Stage Kidney Disease (ESKD). The company's pipeline focuses on multiple advanced treatment modalities, aiming to significantly improve patient outcomes in a critical area of healthcare. Their commitment to addressing complex diseases positions them as a key player in the biopharma innovation landscape.
How much funding has Pathalys Pharma raised?
Pathalys Pharma has raised a total of $255M across 2 funding rounds:
Debt
$150M
Series B
$105M
Debt (2023): $150M with participation from Abingworth, OrbiMed, DaVita, Catalys Pacific, and Carlyle
Series B (2024): $105M led by Catalys Pacific, Samsara BioCapital, and TCG Crossover
Key Investors in Pathalys Pharma
Catalys Pacific
Catalys Pacific is a venture capital firm focused on transforming life sciences innovation by investing in global biotech companies. They specialize in developing targeted therapies for conditions like hypertension and chronic kidney disease, leveraging their network in Japan and the US.
Samsara BioCapital
Samsara BioCapital is an investment firm dedicated to creating transformative therapeutics for patients. They partner with scientists and drug developers to support the next generation of biopharmaceutical breakthroughs.
TCG Crossover
TCG Crossover is a science-driven investment firm focused on advancing disruptive medicines. They invest in breakthrough therapies with the potential to transform healthcare.
What's next for Pathalys Pharma?
The substantial enterprise-level funding and recent strategic investment signal Pathalys Pharma's readiness to advance its late-stage clinical programs towards commercialization. This capital infusion is expected to accelerate the development of their therapeutic candidates, potentially enabling pivotal trials and regulatory submissions. The company's strategic focus on ESKD, a condition with significant unmet needs, suggests a clear path for market penetration and impact. Future growth will likely involve further clinical validation, strategic partnerships, and preparations for market launch, solidifying their position in the biopharmaceutical industry.
See full Pathalys Pharma company page
